In the News

October 2, 2019
The Biosimilars Council applauds bipartisan efforts in the U.S. House of Representatives that would encourage biosimilar uptake and utilization by patients in the Medicare program by aligning patient, provider and taxpayer incentives.
September 17, 2019
Dear Chairman Alexander and Ranking Member Murray: On behalf of the undersigned organizations, we write to express urgent concern about a proposal in the President’s budget request that would undermine trust in the quality of biologic medicines.
August 26, 2019
A coalition of over twenty stakeholders, including the American Cancer Society Cancer Action Network, CVS Health and USP submitted a letter to U.S. Health and Human Services Secretary Azar encouraging the use of biosimilars across Medicare programs.
May 30, 2019
UnitedHealthcare’s (UHC) recent announcement that it will begin preferring brand name biologics over lower priced FDA-approved biosimilars is a step backwards in patient care.
May 13, 2019
The current insulin market lacks significant competition to the detriment of patient access and health and has been characterized as a public health crisis.
May 10, 2019
AAM and the Biosimilars Council applauds the FDA’s timely guidance on interchangeability for biosimilars, particularly its streamlined data and study design requirements.

Want to keep up to date with the biosimilars industry?

Sign up for Biosimilars Council Newsletter to hear about the field, learn about events, and find out how you can make an impact.